enerzair breezhaler (indacaterol acetate/glycopyrronium bromide/mometasone furoate) 150/50/160mcg inhalation powder hard capsule
novartis corporation (malaysia) sdn. bhd. - glycopyrronium bromide; mometasone furoate; indacaterol acetate -
ultibro breezhaler 110/50 indacaterol (as maleate)/ glycopyrronium (as bromide) 110 microgram / 50 microgram powder for inhalation in hard capsule
novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); indacaterol maleate, quantity: 143 microgram (equivalent: indacaterol, qty 110 microgram) - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - ultibro breezhaler 110/50 is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (copd), and for the reduction of exacerbations of copd in patients with a history of exacerbations.
ultibro breezhaler 85 micrograms/43 micrograms, inhalation powder hard capsules
novartis europharm limited - indacaterol, glycopyrronium bromide - inhalation powder, hard capsule - 110 microgram indacaterol and 50 microgram glycopyrronium - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)
ulunar breezhaler
novartis europharm limited - glycopyrronium bromide, indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - ulunar breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).
seebri breezhaler glycopyrronium (as bromide) 50 microgram powder for inhalation (in capsule) blister
novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram) - inhalation, powder for - excipient ingredients: hypromellose; carrageenan; potassium chloride; magnesium stearate; purified water; sunset yellow fcf; lactose monohydrate; strong ammonia solution; ethanol absolute; propylene glycol; potassium hydroxide; butan-1-ol; shellac; iron oxide black; isopropyl alcohol - seebri breezhaler is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (copd).
zimbus breezhaler
novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - asthma - drugs for obstructive airway diseases, - maintenance treatment of asthma in adults whose disease is not adequately controlled.
ultibro breezhaler 85microgram43microgram inhalation powder capsules with device
novartis pharmaceuticals uk ltd - glycopyrronium bromide; indacaterol maleate - inhalation powder - 54microgram/1dose ; 85microgram/1dose
enerzair breezhaler (indacaterol acetateglycopyrronium bromidemometasone furoate) 15050160mcg inhalation powder hard capsules
novartis corporation (malaysia) sdn. bhd. - glycopyrronium bromide; mometasone furoate; indacaterol acetate -
ultibro breezhaler capsule
novartis pharmaceuticals canada inc - glycopyrronium (glycopyrronium bromide); indacaterol (indacaterol maleate) - capsule - 50mcg; 110mcg - glycopyrronium (glycopyrronium bromide) 50mcg; indacaterol (indacaterol maleate) 110mcg - antimuscarinics antispasmodics
utibron neohaler- indacaterol and glycopyrrolate capsule
novartis pharmaceuticals corporation - indacaterol maleate (unii: 2jec1itx7r) (indacaterol - unii:8or09251mq), glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - indacaterol 27.5 ug - utibrontm neohaler® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use: utibron neohaler is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see warnings and precautions (5.1, 5.2)] . all labas are contraindicated in patients with asthma without use of a long-term asthma control medication [see warnings and precautions (5.1)] . utibron neohaler is not indicated for the treatment of asthma. utibron neohaler is contraindicated in patients who have demonstrated hypersensitivity to indacaterol, glycopyrrolate, or to any of the ingredients [see warnings and precautions (5.5)] . teratogenic effects: pregnancy category c there are no adequate and well-controlled studies with utibron neohaler or its individual components, indacaterol and glycopyrrolate, in pregnant women